EcoDrugPlus

Akt Serine/threonine Kinase 1

Ensembl ID : ENSOKIG00005030617
Gene Symbol: AKT1
3 Cross references
144 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSOKIG00005013135
Gene Symbol: AKT1
3 Cross references
180 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSOKIG00005011894
Gene Symbol: AKT3
3 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSOKIG00005017781
Gene Symbol: ABCB1
3 Cross references
164 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSOKIG00005029521
Gene Symbol: ABCC1
1 Cross references
198 Possible Orthologues:

Atp-Binding Cassette Sub-Family C Member 8-Like

Ensembl ID : ENSOKIG00005020688
Gene Symbol: LOC109898452
3 Cross references
223 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 8

Ensembl ID : ENSOKIG00005037341
Gene Symbol: ABCC8
1 Cross references
223 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 9

Ensembl ID : ENSOKIG00005033970
Gene Symbol: ABCC9
1 Cross references
219 Possible Orthologues:

Atp-Sensitive Inward Rectifier Potassium Channel 11-Like

Ensembl ID : ENSOKIG00005021494
Gene Symbol: LOC109897755
3 Cross references
182 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSOKIG00005024243
Gene Symbol: ATP4A
3 Cross references
173 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSOKIG00005000532
Gene Symbol: ATP4A
3 Cross references
177 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSOKIG00005038908
Gene Symbol: ATP4B
3 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).